Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 13, 2007

Evotec Boosts Drug Discovery Business through Deal with Combinature

  • Evotec enhanced its fragment-based drug discovery business through the acquisition of certain assets from Combinature Biopharm. The company gained equipment and expertise in NMR screening and access to the SAR-by-NMR™ intellectual property, licensed from Abbott.

    Evotec thus will be able to integrate NMR-based screening technologies and the SAR-by-NMR technique with its high-throughput, high-concentration biochemical assay approach. The company believes this will augment solutions for its internal pipeline as well as offerings for partnering and collaborative research.

    The transaction also added a library of fragments, bringing the total up to 30,000, which Evotec states makes it the largest available fragment library from an independent fragment-based drug discovery firm.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »